In phase 3 randomized clinical trials of second-generation ALK TKIs (alectinib, brigatinib) in patients with treatment-naive ALK-positive NSCLC, median progression-free survival (PFS) was 25.7 months with alectinib and 24.0 months with brigatinib by independent review committee/blinded independent central review (BICR), or 34.8 months and 30.8 months by investigator assessment, respectively [6-8]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.